COPD & Asthma Clinical Trials | Lung Research Florida

Active Clinical Trials — Now Enrolling

Access the most advanced respiratory treatments available through our cutting-edge research studies. All investigational medications and study-related care provided at no cost to participants.

🔬 Ultra-Long-Acting Biologics

🧬 Dual-Pathway Targeting

🎯 Precision Medicine

8 Active Studies

$0 Cost to Participants

100% Study-Related Care Covered

AIRLYMPUS: Novel Subcutaneous Biologic for High-Risk Severe Asthma

Now Enrolling Severe Asthma Pre-Biologic Innovation

A new injectable biologic for severe asthma that has not responded to standard treatment. This innovative subcutaneous therapy targets inflammatory pathways in high-risk patients not yet eligible for traditional biologics, potentially preventing progression to more severe disease.

Study Overview

This 52-week Phase 2 study investigates a novel subcutaneous treatment specifically designed for high-risk asthma patients on medium-dose inhaled therapy who do not yet qualify for traditional biologics. This innovative approach targets inflammatory pathways earlier in the disease process, potentially preventing progression to severe asthma requiring more intensive treatments.

Key Study Features

Early Intervention: Targets inflammation before severe asthma develops
Subcutaneous Delivery: Convenient injection therapy
Exacerbation Prevention: Focus on reducing asthma attacks
Lung Function Improvement: Enhanced FEV1 outcomes
Bridge Therapy: Fills gap between standard care and biologics

Am I Eligible?

You May Qualify If You:

Are 18-75 years old
Have persistent or severe asthma uncontrolled on current inhaled therapy or standard biologics
Had at least 1 asthma exacerbation in past year
Have blood eosinophils >300 cells/μL at screening
Have FeNO >50 ppb at screening
Show reversibility on spirometry or have documented history

You May NOT Qualify If You:

Had respiratory infection within 4 weeks
Used anti-IgE therapy within 130 days
Used other biologics within 2 months or 5 half-lives
Are using LAMA in addition to ICS/LABA
Have significant other medical conditions
Are pregnant or planning pregnancy

Study Facts

Duration: 52 weeks

Visits: Monthly visits

Treatment: Subcutaneous injection

Design: Randomized, double-blind, placebo-controlled

Participation Benefits

Free investigational subcutaneous therapy
Regular monitoring of asthma control
Advanced biomarker testing
Comprehensive lung function assessments
Early access to innovative treatment
Close specialist monitoring
Compensation for time and travel

Check Your Eligibility Call Research Line

IMAGINE: Ultra-Long-Acting IL-5 Therapy with Advanced CT Imaging

Now Enrolling Severe Asthma 6-Month Dosing

Fewer injections, longer-acting relief, and deep lung monitoring via CT. This revolutionary IL-5 antagonist requires only two doses per year combined with advanced CT imaging to document lung improvements. No placebo group — all participants receive active treatment.

Study Overview

The IMAGINE study is a 52-week Phase 3b trial evaluating an ultra-long-acting IL-5 antagonist administered just twice yearly. This study uses high-resolution CT scanning to document structural lung improvements over time. With no placebo group, all participants receive active treatment, making this an exceptional opportunity for patients with eosinophilic severe asthma.

Key Study Features

Ultra-Long-Acting: Only 2 doses per year (every 26 weeks)
No Placebo: All participants receive active treatment
CT Imaging: Visualize lung improvements over time
Eosinophil Control: Targets eosinophilic inflammation
Bronchoscopy Option: Optional substudy with lung sampling

Am I Eligible?

You May Qualify If You:

Are 18-75 years old
Have blood eosinophils >300 cells/μL
Had ≥2 asthma exacerbations in past year
Have FeNO >25 ppb at screening
On medium/high-dose ICS >12 months plus controller
Can undergo CT scanning (no metal implants)
Seeking extended dosing intervals and objective lung monitoring

You May NOT Qualify If You:

Received anti-IL-5 therapy within 12 months
Failed previous anti-IL-5/5R therapy
Used other biologics within 12 months
Had exacerbation within 6 weeks
Have pacemaker or metal prosthesis
Used investigational drugs recently

Study Facts

Duration: 52 weeks

Visits: Every 3-6 months

Treatment: SC injection every 26 weeks

Special: HRCT imaging included

Participation Benefits

Guaranteed active treatment (no placebo)
Ultra-convenient 6-month dosing
Advanced HRCT lung imaging
Comprehensive biomarker testing
Optional bronchoscopy substudy
See your lung improvements on CT
Expert asthma specialist care

Check Your Eligibility Call Research Line

Lunsekimig: Sanofi Bispecific Antibody for Severe Asthma

Now Enrolling Severe Asthma Dual-Target Biologic

A Sanofi-sponsored bispecific antibody that targets two key inflammatory pathways driving severe asthma simultaneously. NCT06676319 — now enrolling adults aged 18 to 80 at Lung Research Florida.

Study Overview

Lunsekimig is an investigational bispecific antibody developed by Sanofi that targets two inflammatory mediators involved in severe asthma. By blocking both pathways with a single molecule, lunsekimig aims to provide broader, more effective control of airway inflammation in patients with persistent, difficult-to-treat asthma. This study is being conducted at Lung Research Florida under the direction of Dr. Frank Hull.

Key Study Features

Bispecific Design: Single antibody targeting two inflammatory pathways
Broad Age Range: Adults 18–80 eligible to participate
Sanofi Sponsor: World-class pharmaceutical company with deep respiratory expertise
Expert PI: Dr. Frank Hull, 20+ years of pulmonary research experience
No Cost: All study-related care and investigational medication provided free

ClinicalTrials.gov identifier: NCT06676319

Am I Eligible?

You May Qualify If You:

Are 18–80 years old
Have severe or uncontrolled asthma
Have had asthma exacerbations in the past year
Are on current asthma therapy
Are willing to attend regular study visits in Plantation, FL

You May NOT Qualify If You:

Have active lung infection
Have used certain biologics recently
Are pregnant or planning pregnancy
Have significant other medical conditions

Full eligibility criteria will be confirmed at your free screening visit. Call our research line to find out if you qualify.

Study Facts

Ages: 18–80

Sponsor: Sanofi

NCT: NCT06676319

Treatment: Bispecific antibody (lunsekimig)

Participation Benefits

Free investigational bispecific antibody therapy
Comprehensive asthma monitoring
Regular lung function testing
Expert pulmonologist care with Dr. Hull
Compensation for time and travel
Early access to innovative Sanofi therapy

Check Your Eligibility Call Research Line

ENDURA: IL-5 Inhibition for Eosinophilic COPD Exacerbators

Now Enrolling Eosinophilic COPD Precision Medicine

Targets the specific inflammatory pathway driving your COPD flare-ups. This precision medicine approach identifies COPD patients with elevated eosinophils most likely to benefit from targeted anti-eosinophilic treatment.

Study Overview

The ENDURA study evaluates IL-5 inhibition in carefully selected COPD patients with eosinophilic inflammation. This represents a precision medicine approach to COPD, targeting treatment to patients with specific inflammatory phenotypes who are most likely to respond. The study focuses on frequent exacerbators with elevated eosinophils ages 40-80.

Key Study Features

Targeted Therapy: For eosinophilic COPD only
IL-5 Inhibition: Reduces eosinophilic inflammation
Exacerbation Focus: For frequent exacerbators
Biomarker-Driven: Eosinophil and Type 2 markers
Personalized Approach: Precision medicine for COPD

Am I Eligible?

You May Qualify If You:

Are 40-80 years old
Have confirmed COPD with frequent exacerbations
Have elevated blood eosinophils
Have evidence of Type 2 inflammation
Are on optimal COPD therapy
Have history of ≥2 exacerbations yearly
Meet biomarker criteria

You May NOT Qualify If You:

Have primary asthma diagnosis
Have low eosinophil counts
Have received recent biologic therapy
Have active parasitic infection
Have immunodeficiency disorders
Are unable to use study medications

Study Facts

Ages: 40-80

Treatment: IL-5 antagonist

Focus: Eosinophilic COPD

Approach: Precision medicine

Participation Benefits

Targeted IL-5 therapy
Precision medicine approach
Regular eosinophil monitoring
Comprehensive COPD care
Biomarker assessments
Exacerbation prevention focus
Expert specialist management

Check Your Eligibility Call Research Line

THESEUS: Novel Nanobody Dual IL-13/TSLP Inhibition for COPD

Now Enrolling COPD Exacerbations Dual-Target Nanobody

Attacks COPD inflammation from two angles simultaneously. This revolutionary nanobody technology targets both IL-13 and TSLP pathways with a single molecule — designed for COPD patients with inadequate response to standard inhaled therapy.

Study Overview

The THESEUS study investigates an innovative nanobody that uniquely targets both IL-13 and TSLP inflammatory pathways simultaneously. Designed for moderate to very severe COPD patients with type-2 inflammatory phenotype and frequent exacerbations, this dual-action approach addresses multiple inflammatory mechanisms with a single therapy for ages 40-80.

Key Study Features

Dual Inhibition: Simultaneous IL-13 and TSLP blockade
Nanobody Design: Enhanced tissue penetration and stability
Exacerbation Focus: For high-risk COPD patients
Eosinophilic COPD: Particularly effective for elevated eosinophils
Inadequate Response: For those not responding to LAMA/LABA/ICS

Am I Eligible?

You May Qualify If You:

Are 40-80 years old
Have moderate to very severe COPD (≥12 months)
Have COPD with type-2 inflammatory phenotype
Post-bronchodilator FEV1 ≥20% and ≤70% predicted
Smoking history ≥10 pack-years
CAT score ≥10
≥2 moderate or ≥1 severe exacerbation in past year
On triple therapy (LABA+LAMA+ICS) ≥3 months
Blood eosinophils ≥150 cells/μL

You May NOT Qualify If You:

Have asthma diagnosis
Have other significant lung diseases
Require oxygen >4.0 L/min
Recent COPD exacerbation (within 4 weeks)
Recent MI, TIA, or stroke (<6 months)
Heart failure NYHA Class III/IV

Study Facts

Duration: 48 weeks treatment

Visits: Monthly monitoring

Treatment: Subcutaneous nanobody

Focus: Exacerbation reduction

Participation Benefits

Free innovative nanobody therapy
Dual-pathway inflammation control
Regular lung function monitoring
Quality of life assessments
Comprehensive COPD management
Biomarker monitoring
Expert pulmonologist care

Check Your Eligibility Call Research Line

PRESTO: IRAK4 Inhibitor for COPD Inflammation

Now Enrolling COPD Novel Mechanism

Targets the upstream inflammatory signal driving COPD — a new mechanism. This first-in-class IRAK4 pathway inhibitor addresses chronic inflammation through toll-like receptors and IL-1 family pathways with a convenient oral tablet for patients with persistent airway inflammation.

Study Overview

The PRESTO study investigates an IRAK4 inhibitor that blocks key inflammatory signals in COPD. By targeting toll-like receptors and IL-1 family pathways, this oral medication addresses the underlying chronic inflammation that drives COPD progression and exacerbations. Designed for patients ages 40-80 with persistent airway inflammation despite maximal therapy.

Key Study Features

New Mechanism: IRAK4 inhibitor for COPD
Oral Therapy: Convenient tablet formulation
Inflammation Control: Targets TLR and IL-1 pathways
Exacerbation Prevention: Reduces inflammatory triggers
Disease Modification: Potential to slow progression

Am I Eligible?

You May Qualify If You:

Are 40-80 years old
Have moderate to very severe COPD ≥12 months
Have persistent airway inflammation despite maximal therapy
On stable triple or dual therapy ≥3 months
≥2 moderate or ≥1 severe exacerbation in past year
Documentation of exacerbations available

You May NOT Qualify If You:

Have asthma or other lung diseases
Have unstable cardiovascular disease
Recent MI (<6 months)
Have active tuberculosis
Have HIV or hepatitis B/C
Have significant liver/kidney dysfunction

Study Facts

Ages: 40-80

Treatment: Oral IRAK4 inhibitor

Innovation: Novel mechanism for COPD

Visits: Regular monitoring

Participation Benefits

Access to novel IRAK4 inhibitor
Convenient oral medication
Comprehensive inflammation monitoring
Regular safety assessments
Exacerbation tracking
Potential disease modification
Expert COPD management

Check Your Eligibility Call Research Line

THARROS: Triple vs Dual Therapy for Cardiac Events in COPD

Now Enrolling COPD Cardiac Protection

Could triple therapy protect your heart and lungs better than dual therapy? This landmark Phase 3/4 study compares triple inhaled therapy versus dual therapy for reducing heart attacks and strokes in COPD patients with documented cardiovascular risk.

Study Overview

This pivotal study investigates whether adding an inhaled corticosteroid to dual bronchodilator therapy can significantly reduce major cardiovascular events in COPD patients at high cardiac risk. This study focuses not just on respiratory symptoms but on comprehensive cardiovascular protection for patients ages 40-80 with confirmed cardiovascular comorbidity.

Key Study Features

Cardiovascular Focus: Evaluating reduction in heart attacks and strokes
Comprehensive Protection: Dual lung and heart outcomes
Inflammation Control: Anti-inflammatory approach to systemic COPD effects
Risk Stratification: Focus on high cardiovascular risk patients
Long-term Outcomes: Extended follow-up for major cardiac events

Am I Eligible?

You May Qualify If You:

Are 40-80 years old
Have confirmed COPD diagnosis (FEV1/FVC ratio < 70%)
Have smoking history ≥10 pack-years
Have blood eosinophils ≥100 cells/mm³
Have CAT score ≥10
Have cardiovascular risk factors (prior heart attack, stents, or 3+ risk factors)
Have not used inhaled corticosteroids >2 months in past year

You May NOT Qualify If You:

Have asthma diagnosis
Are on long-term inhaled corticosteroids
Have severe liver or kidney disease
Have unstable cardiovascular conditions
Cannot use MDI devices properly
Have contraindications to study medications

Study Facts

Duration: Up to 4 years follow-up

Visits: Every 3-6 months

Treatment: Triple or dual inhaled therapy

Primary Focus: Heart attack and stroke prevention

Participation Benefits

Free triple or dual combination inhaler therapy
Comprehensive cardiovascular monitoring
Regular cardiac biomarker testing
Advanced lung function assessments
Cardiovascular risk evaluation
Close monitoring by specialists
Contribution to landmark cardiac protection research

Check Your Eligibility Call Research Line

VENTO: IL-33 Inhibition to Reduce Bronchiectasis Exacerbations

Now Enrolling Bronchiectasis Novel Biologic

May reduce the recurring infections driving your bronchiectasis flare-ups. This study investigates IL-33 inhibition as a new approach to reducing exacerbations in patients with confirmed bronchiectasis and frequent lung infections.

Study Overview

The VENTO study evaluates an IL-33 inhibitor for patients with confirmed bronchiectasis who experience recurrent pulmonary exacerbations. IL-33 is an alarmin cytokine involved in the inflammatory cascade that drives bronchiectasis flare-ups. By targeting this pathway, VENTO aims to reduce exacerbation frequency and improve quality of life for patients with this chronic lung condition.

Key Study Features

Novel Target: IL-33 inhibition to reduce airway inflammation
Exacerbation Focus: For patients with 2 or more flare-ups per year
Confirmed Bronchiectasis: HRCT diagnosis required
Infection Reduction: May reduce recurrent lung infections
Quality of Life: Focus on improving daily functioning

Am I Eligible?

You May Qualify If You:

Are 18-85 years old
Have confirmed bronchiectasis on HRCT scan
Have had 2 or more exacerbations in the past year
Have a history of recurrent lung infections
Are on stable bronchiectasis management therapy
Are able to provide informed consent

You May NOT Qualify If You:

Have cystic fibrosis
Have active pulmonary tuberculosis
Have had recent severe exacerbation requiring hospitalization
Are currently on immunosuppressive therapy
Have significant other medical conditions
Are pregnant or planning pregnancy

Study Facts

Ages: 18-85

Treatment: IL-33 inhibitor (biologic)

Focus: Exacerbation reduction

Requirement: HRCT-confirmed bronchiectasis

Participation Benefits

Free investigational IL-33 biologic therapy
Regular pulmonary function monitoring
Comprehensive exacerbation tracking
Quality of life assessments
Specialist respiratory care throughout study
Compensation for time and travel
Contribute to bronchiectasis research

Check Your Eligibility Call Research Line

CLEAR: Pseudomonas-Targeted Antibody for Bronchiectasis

Now Enrolling Bronchiectasis Novel Antibody

Targeting the Pseudomonas aeruginosa bacterial infection that drives chronic lung damage in bronchiectasis. The CLEAR study evaluates a new investigational antibody designed to help patients who have not been able to eliminate this persistent infection.

Study Overview

The CLEAR study is evaluating a new investigational antibody designed to help patients with bronchiectasis who have chronic Pseudomonas aeruginosa infection in their lungs. This type of bacterial infection is common in bronchiectasis and is associated with more frequent lung infections (exacerbations), hospitalizations, and worsening lung health over time.

This pseudomonal antibody is designed to target and block specific structures that Pseudomonas bacteria use to infect lung cells and form protective biofilms that make them harder for the immune system and antibiotics to eliminate. By disrupting these mechanisms, the CLEAR study aims to reduce lung flare-ups, improve respiratory symptoms, and potentially improve quality of life for people living with bronchiectasis.

Key Study Features

Novel Target: Antibody blocking Pseudomonas aeruginosa infection and biofilm formation
Exacerbation Reduction: Aims to reduce frequency of lung flare-ups
Infection Focus: For patients with confirmed chronic Pseudomonas colonization
Quality of Life: Focus on improving respiratory symptoms and daily functioning

Am I Eligible?

You May Qualify If You:

Are 12 years of age or older
Have confirmed bronchiectasis on CT scan (at least 1 lobe affected)
Have had 2 or more moderate exacerbations OR 1 severe (hospitalization) in the past 12 months
Have had a positive Pseudomonas aeruginosa airway sample at least once in the past 24 months
Have been clinically stable for at least 4 weeks prior to enrollment

You May NOT Qualify If You:

Have cystic fibrosis
Are not clinically stable at the time of enrollment
Have significant other medical conditions that may interfere with the study
Are pregnant or planning pregnancy

Study Facts

Ages: 12+

Treatment: Investigational Pseudomonas antibody

Focus: Exacerbation reduction in Pseudomonas-positive bronchiectasis

Requirement: CT-confirmed bronchiectasis + Pseudomonas history

Participation Benefits

Free investigational antibody therapy
Regular pulmonary monitoring and specialist care
Comprehensive exacerbation tracking
Quality of life assessments
Compensation for time and travel
Contribute to bronchiectasis research

Check Your Eligibility Call Research Line

Chronic Cough Research

Study Closed — Not Currently Recruiting

Our research center previously conducted a clinical trial for patients with chronic, unexplained cough lasting one year or more. That study has concluded.

We hope to bring additional chronic cough research opportunities to our patients in the future. If you have been living with a persistent cough that has not responded to standard treatments, we encourage you to check back periodically for updates on new trials as they become available.

For general inquiries, call our research line: 954-520-7296 x1

Referring Physicians: Enroll Your Patients in Active Research Studies

Lung Research Florida offers your patients access to advanced respiratory treatments across asthma, COPD, and bronchiectasis — including ultra-long-acting biologics, precision medicine, and novel anti-inflammatory approaches not available through standard care in South Florida.

Advanced Therapies

Ultra-long-acting biologics requiring only 2 injections yearly, dual-pathway nanobodies, and precision medicine for complex respiratory cases

Comprehensive Reporting

Detailed progress reports, biomarker analysis, and treatment outcomes shared with referring physicians throughout study participation

Fast-Track Enrollment

Same-day physician referral processing with eligibility assessment typically completed within 48 hours

View Physician Resources Call Research Referral Line

Interested in Participating in a Clinical Trial?

Our specialized research coordinators are available to discuss these studies and determine your eligibility. All consultations are free, confidential, and available in English and Spanish.

Research Enrollment

954-520-7296 x1

Monday - Friday: 8:00 AM - 6:00 PM
Saturday: 9:00 AM - 2:00 PM

Email Research Team

Response within 4 hours during business days

Visit Our Research Center

Lung Research Florida
Research Facility of Advanced Asthma Clinic
10059 NW 1st Court
Plantation, FL 33324